Clinical experience with idarucizumab prior to thrombolytic therapy of cerebral infarction in the Sverdlovsk region

Introduction. In recent years, the use of oral anticoagulants for prevention ischemic strokes (IS) in patients with atrial fibrillation (AF), as well deep vein thrombosis and thromboembolism has been increasing clinical practice. According to epidemiological studies, account about 85% all AMI. Cardioembolic (CES), which develop due embolism cerebral vessels from heart chambers, deserve special attention. The presence AF is associated a twofold increase risk death cardiovascular disease any cause. Timely anticoagulant therapy can reduce thromboembolic complications improve prognosis. Materials Methods. authors present observation 47-year-old female patient diagnosed venous insufficiency, who took dabigatran 150 mg twice day year, developed IS left-sided pronounced hemiparesis. After 170 minutes development stroke, idarucizumab was administered neutralize effect thrombolytic (TLT) performed. Results. Twenty-four hours after TLT, National Institutes Health Stroke Scale (NIHSS) score decreased 16 6. A repeat CT scan brain revealed focus ischemia right frontal, parietal, temporal lobes. On 19th AI, 2 times resumed. Conclusion. presented confirms that AI against background dabigatran, administration safe allows TLT.